HK1080377A1 - Use of neurotoxin therapy for treatment of urologic and related disorders - Google Patents

Use of neurotoxin therapy for treatment of urologic and related disorders

Info

Publication number
HK1080377A1
HK1080377A1 HK06100417A HK06100417A HK1080377A1 HK 1080377 A1 HK1080377 A1 HK 1080377A1 HK 06100417 A HK06100417 A HK 06100417A HK 06100417 A HK06100417 A HK 06100417A HK 1080377 A1 HK1080377 A1 HK 1080377A1
Authority
HK
Hong Kong
Prior art keywords
urologic
treatment
related disorders
neurotoxin therapy
neurogenic bladder
Prior art date
Application number
HK06100417A
Other languages
English (en)
Inventor
Richard A Schmidt
Original Assignee
Univ Colorado
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21978526&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1080377(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Colorado filed Critical Univ Colorado
Publication of HK1080377A1 publication Critical patent/HK1080377A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK06100417A 1997-07-15 2004-09-08 Use of neurotoxin therapy for treatment of urologic and related disorders HK1080377A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5258097P 1997-07-15 1997-07-15
HK04106802.1A HK1064044A1 (en) 1997-07-15 2004-09-08 Use of neurotoxin therapy for treatment of urologic and related disorders

Publications (1)

Publication Number Publication Date
HK1080377A1 true HK1080377A1 (en) 2006-04-28

Family

ID=21978526

Family Applications (4)

Application Number Title Priority Date Filing Date
HK04106802.1A HK1064044A1 (en) 1997-07-15 2004-09-08 Use of neurotoxin therapy for treatment of urologic and related disorders
HK06112481.5A HK1091750A1 (en) 1997-07-15 2004-09-08 Use of neurotoxin therapy for treatment of urologic and related disorders
HK06100417A HK1080377A1 (en) 1997-07-15 2004-09-08 Use of neurotoxin therapy for treatment of urologic and related disorders
HK08111205.0A HK1119396A1 (en) 1997-07-15 2008-10-09 Use of botulinum toxin therapy for treatment of urge type dysfunction

Family Applications Before (2)

Application Number Title Priority Date Filing Date
HK04106802.1A HK1064044A1 (en) 1997-07-15 2004-09-08 Use of neurotoxin therapy for treatment of urologic and related disorders
HK06112481.5A HK1091750A1 (en) 1997-07-15 2004-09-08 Use of neurotoxin therapy for treatment of urologic and related disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK08111205.0A HK1119396A1 (en) 1997-07-15 2008-10-09 Use of botulinum toxin therapy for treatment of urge type dysfunction

Country Status (16)

Country Link
US (5) US6365164B1 (de)
EP (8) EP1011695B2 (de)
JP (9) JP3692033B2 (de)
KR (1) KR100544060B1 (de)
CN (5) CN1803189B (de)
AT (5) ATE320815T1 (de)
AU (2) AU743085B2 (de)
CA (5) CA2521392A1 (de)
CY (3) CY1105816T1 (de)
DE (4) DE69841291D1 (de)
DK (6) DK2145629T3 (de)
ES (6) ES2385130T3 (de)
HK (4) HK1064044A1 (de)
LU (2) LU92055I2 (de)
PT (5) PT1011695E (de)
WO (1) WO1999003483A1 (de)

Families Citing this family (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7455845B2 (en) 1997-07-15 2008-11-25 The Regents Of The University Of Colorado Use of neurotoxin therapy for treatment of urologic and related disorders related to lowering elevated bladder pressure
US9066943B2 (en) 1997-07-15 2015-06-30 The Regents Of The University Of Colorado Use of botulinum toxin therapy for treatment of urological neurological conditions
US7449192B2 (en) 1997-07-15 2008-11-11 The Regents Of The University Of Colorado Use of neurotoxin therapy for treatment of urologic and related disorders related to neurogenic bladder dysfunction
ES2385130T3 (es) 1997-07-15 2012-07-18 The Regents Of The University Of Colorado, A Body Corporate Uso de terapia con neurotoxinas para el tratamiento de enfermedades urológicas y de enfermedades relacionadas
US7470431B2 (en) * 1997-07-15 2008-12-30 The Regents Of The University Of Colorado Use of neurotoxin therapy for treatment of urological-neurological disorders associated with prostate cancer
US6450509B2 (en) * 1999-04-01 2002-09-17 Heeling Sports Limited Heeling apparatus and method
DE19925739A1 (de) * 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
US7838007B2 (en) 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating mammary gland disorders
US7838008B2 (en) * 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating diverse cancers
US6821520B2 (en) 2000-02-15 2004-11-23 Allergan, Inc. Clostridial toxin therapy for Hashimoto's thyroiditis
US6773711B2 (en) 2000-02-15 2004-08-10 Allergan, Inc. Botulinum toxin therapy for Hashimoto's thyroiditis
US6524580B1 (en) 2000-02-15 2003-02-25 Allergan Sales, Inc. Method for treating thyroid disorders
US6358513B1 (en) 2000-02-15 2002-03-19 Allergan Sales, Inc. Method for treating Hashimoto's thyroiditis
US20050214327A1 (en) * 2000-06-02 2005-09-29 Allergan, Inc. Neurotoxin-containing suppositories and related methods
US20040170665A1 (en) * 2000-06-02 2004-09-02 Allergan, Inc. Intravitreal botulinum toxin implant
US20040033241A1 (en) * 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
US6306403B1 (en) * 2000-06-14 2001-10-23 Allergan Sales, Inc. Method for treating parkinson's disease with a botulinum toxin
US7491799B2 (en) * 2000-07-21 2009-02-17 Allergan, Inc. Modified botulinum neurotoxins
US20040219619A1 (en) * 2000-07-21 2004-11-04 Ester Fernandez-Salas Methods of identifying compounds that alter toxin persistence and/or protease activity
US6903187B1 (en) * 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
US7691983B2 (en) * 2000-07-21 2010-04-06 Allergan, Inc. Chimera botulinum toxin type E
GB0029125D0 (en) * 2000-11-29 2001-01-10 Specialistkliniken I Varberg H Novel treatment
JP4707254B2 (ja) * 2001-04-24 2011-06-22 クミアイ化学工業株式会社 粒状組成物及びその製造方法
BR0210873A (pt) * 2001-07-10 2004-06-22 Yamanouchi Pharma Co Ltd Composição farmacêutica para terapia de cistite intersticial
US6984375B2 (en) * 2001-08-03 2006-01-10 Allergan, Inc. Nuclei density and nuclei area methods for determining effects of a botulinum toxin on muscles
WO2003015698A2 (en) * 2001-08-13 2003-02-27 University Of Pittsburgh Application of lipid vehicles and use for drug delivery
US8110217B2 (en) * 2001-08-13 2012-02-07 University Of Pittsburgh Sphingomyelin liposomes for the treatment of hyperactive bladder disorders
US20100104631A1 (en) * 2001-08-13 2010-04-29 Lipella Pharmaceuticals Inc. Method of treatment for bladder dysfunction
US6623742B2 (en) 2001-09-17 2003-09-23 Allergan, Inc. Methods for treating fibromyalgia
US7255866B2 (en) 2001-09-17 2007-08-14 Allergan, Inc. Botulinum toxin therapy for fibromyalgia
ES2401570T3 (es) 2001-11-15 2013-04-22 Phytotox Limited Composiciones farmacéuticas que contienen 3,4-propinoperhidropurinas y usos de las mismas para bloquear la transmisión neuronal
US7763663B2 (en) * 2001-12-19 2010-07-27 University Of Massachusetts Polysaccharide-containing block copolymer particles and uses thereof
US6688311B2 (en) 2002-03-14 2004-02-10 Allergan, Inc. Method for determining effect of a clostridial toxin upon a muscle
US7140371B2 (en) 2002-03-14 2006-11-28 Allergan, Inc. Surface topography method for determining effects of a botulinum toxin upon a muscle and for comparing botulinum toxins
US7691394B2 (en) * 2002-05-28 2010-04-06 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations
US6776991B2 (en) * 2002-06-26 2004-08-17 Allergan, Inc. Methods for treating priapism
WO2004010934A2 (en) * 2002-07-29 2004-02-05 Rajiv Doshi Methods for the use of neurotoxin in the treatment of urologic disorders
US20040086532A1 (en) * 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration
US7238357B2 (en) * 2002-11-05 2007-07-03 Allergan, Inc. Methods for treating ulcers and gastroesophageal reflux disease
GB2398636A (en) * 2003-02-21 2004-08-25 Ipsen Ltd Method for determining the quantity of pre-synaptic neuromuscular blocking substance contained in a sample
US8071550B2 (en) * 2003-03-03 2011-12-06 Allergan, Inc. Methods for treating uterine disorders
EP1599219A1 (de) * 2003-03-06 2005-11-30 Botulinum Toxin Research Associates, Inc. Behandlung von chronischer chalazion und hordeolum mit botulinustoxin
ZA200506715B (en) * 2003-03-06 2007-05-30 Botulinum Toxin Res Ass Inc Treatment of sinusitis related chronic facial pain and headache with botulinum toxin
US7393537B2 (en) * 2003-04-25 2008-07-01 Allergan, Inc. Botulinum toxin for treatment of obsessive compulsive finger biting disorder
US7390496B2 (en) * 2003-04-25 2008-06-24 Allergan, Inc. Therapeutic treatments for repetitive hand washing
US7396535B2 (en) * 2003-04-25 2008-07-08 Ackerman Alan H Therapy for obsessive compulsive head banging
US7393538B2 (en) * 2003-04-25 2008-07-01 Ackerman Alan H Clostridial toxin treatment for dermatillomania
US7422753B2 (en) * 2003-04-25 2008-09-09 Allergan, Inc. Methods for treating trichotillomania
US6838434B2 (en) * 2003-05-02 2005-01-04 Allergan, Inc. Methods for treating sinus headache
US7220422B2 (en) * 2003-05-20 2007-05-22 Allergan, Inc. Methods and compositions for treating eye disorders
US20040253274A1 (en) * 2003-06-11 2004-12-16 Allergan, Inc. Use of a clostridial toxin to reduce appetite
US20050013850A1 (en) * 2003-07-15 2005-01-20 Caers Jan K. Device to assist hyperhydrosis therapy
US8734810B2 (en) 2003-10-29 2014-05-27 Allergan, Inc. Botulinum toxin treatments of neurological and neuropsychiatric disorders
US8617572B2 (en) * 2003-10-29 2013-12-31 Allergan, Inc. Botulinum toxin treatments of depression
US8609113B2 (en) 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
US8609112B2 (en) 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
US7437194B2 (en) * 2003-10-31 2008-10-14 Medtronic, Inc. Stimulating the prostate gland
US20050096549A1 (en) * 2003-10-31 2005-05-05 Medtronic, Inc. Techniques for transperineal delivery of a denervating agent to the prostate gland
US20050096550A1 (en) * 2003-10-31 2005-05-05 Medtronic, Inc. Techniques for transrectal delivery of a denervating agent to the prostate gland
US20050096629A1 (en) * 2003-10-31 2005-05-05 Medtronic, Inc. Techniques for transurethral delivery of a denervating agent to the prostate gland
US7172764B2 (en) * 2003-11-17 2007-02-06 Allergan, Inc. Rescue agents for treating botulinum toxin intoxications
GB0328060D0 (en) * 2003-12-04 2004-01-07 Sod Conseils Rech Applic Botulinum toxin treatment
US20050129677A1 (en) * 2003-12-10 2005-06-16 Shengwen Li Lipid rafts and clostridial toxins
US20050148935A1 (en) * 2003-12-29 2005-07-07 Rozalina Dimitrova Botulinum toxin injection guide
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
JP2007538010A (ja) * 2004-05-07 2007-12-27 ファイトトックス リミテッド フィコトキシンの経皮投与
CA2607589A1 (en) * 2004-05-07 2005-11-24 Phytotox Limited Methods of treating wounds with gonyautoxins
WO2006130161A2 (en) * 2004-07-21 2006-12-07 The Cornell Research Foundation, Inc. Therapeutic compounds derived from spider venom and their method of use
US20060024794A1 (en) * 2004-07-30 2006-02-02 Shengwen Li Novel methods for production of di-chain botulinum toxin
EP1778279B1 (de) 2004-08-04 2014-12-03 Ipsen Biopharm Limited Pharmazeutische zusammensetzung mit botulinum neurotoxin a2
EP1776137B1 (de) * 2004-08-04 2014-11-26 Ipsen Biopharm Limited Pharmazeutische zusammensetzung enthaltend botulinum neurotoxin a2
US7429386B2 (en) 2004-09-03 2008-09-30 Allergan, Inc. Stretch mark treatment
US7179474B2 (en) * 2004-09-03 2007-02-20 Allergan, Inc. Methods for treating a buttock deformity
US7727537B2 (en) 2005-02-14 2010-06-01 Dpm Therapeutics Corp. Stabilized compositions for topical administration and methods of making same
CN1946738A (zh) 2005-03-03 2007-04-11 阿勒根公司 用于纯化肉毒毒素的不含动物产物的系统和方法
US7419675B2 (en) * 2005-05-26 2008-09-02 Allergan, Inc. Method for treating peritoneal adhesions
EP1896112A4 (de) * 2005-06-07 2011-04-27 A M S Res Corp Injektionsführsystem und verfahren
US20070038089A1 (en) * 2005-06-29 2007-02-15 Olympus Medical Systems Corp. Transurethral diagnostic method and treatment method using ultrasonic endoscope
JP5368793B2 (ja) * 2005-07-18 2013-12-18 ユニバーシティ オブ マサチューセッツ ロウエル ナノエマルジョンを製造および使用するための組成物および方法
US7910116B2 (en) * 2005-08-24 2011-03-22 Allergan, Inc. Use of a botulinum toxin to improve gastric emptying and/or to treat GERD
WO2007044748A2 (en) * 2005-10-11 2007-04-19 University Of Pittsburgh Sphingomyelin liposomes for the treatment of hyperactive bladder disorders
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
HUE054852T2 (hu) 2005-12-01 2021-10-28 Univ Massachusetts Lowell Botulinum nanoemulziók
US20090312696A1 (en) * 2005-12-28 2009-12-17 Copa Vincent G Devices, Systems, and Related Methods for Delivery of Fluid to Tissue
US7770674B2 (en) * 2006-03-14 2010-08-10 Fallbrook Technologies Inc. Wheel chair
US7794386B2 (en) 2006-03-15 2010-09-14 Allergan, Inc. Methods for facilitating weight loss
US7811586B2 (en) * 2006-05-02 2010-10-12 Allergan, Inc. Methods for alleviating testicular pain
US20090304747A1 (en) * 2006-05-16 2009-12-10 Mayo Foundation For Medical Education And Research Use of dmso and botulinum toxin therapy for urinary incontinence and related disorders
AR061669A1 (es) 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica
US10792344B2 (en) 2006-06-29 2020-10-06 Merz Pharma Gmbh & Co. Kgaa High frequency application of botulinum toxin therapy
US20080092910A1 (en) * 2006-10-18 2008-04-24 Allergan, Inc. Apparatus and method for treating obesity using neurotoxins in conjunction with bariatric procedures
US20080113051A1 (en) * 2006-11-13 2008-05-15 Allergan, Inc. Methods for alleviating tattoo pain
MX2009005726A (es) 2006-12-01 2009-09-28 Anterios Inc Nanoparticulas peptidicas y usos de las mismas.
AU2007329579A1 (en) * 2006-12-01 2008-06-12 Anterios, Inc. Amphiphilic entity nanoparticles
EP2583687B1 (de) * 2007-02-15 2014-08-27 Allergan, Inc. Botulintoxinzusammensetzungen zur behandlung von hyperhydrose
KR20100050443A (ko) 2007-05-31 2010-05-13 안테리오스, 인코퍼레이티드 핵산 나노입자 및 이의 용도
NZ585108A (en) 2007-10-23 2012-09-28 Allergan Inc Methods of treating urogenital-neurological disorders using modified clostridial toxins
US8470337B2 (en) * 2008-03-13 2013-06-25 Allergan, Inc. Therapeutic treatments using botulinum neurotoxin
ES2761664T3 (es) * 2008-06-26 2020-05-20 Anterios Inc Entrega dérmica
US9066851B2 (en) 2008-12-04 2015-06-30 Botulinum Toxin Research Associates, Inc. Extended length botulinum toxin formulation for human or mammalian use
US8278279B2 (en) * 2008-12-15 2012-10-02 Protox Therapeutics Corp. Method for treating prostatitis utilizing modified pore-forming protein proaerolysin
WO2010078403A2 (en) * 2008-12-30 2010-07-08 Lipella Pharmaceuticals Inc. Methods and compositions for diagnosing urological disorders
US8133491B1 (en) 2009-01-30 2012-03-13 The University Of Toledo Compositions and methods for treatment of hyperplastic disorders
AU2010221435B2 (en) 2009-03-06 2014-06-19 Allergan, Inc. Clostridial toxin to improve ejaculate
US20100303789A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Neurotrophin Retargeted Endopepidases
US20100303794A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Urogenital-Neurological Disorders Using Glucagon Like Hormone Retargeted Endopepidases
US20100303798A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Urogenital-Neurological Disorders Using Neurotrophin Retargeted Endopepidases
US20100303791A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Glucagon Like Hormone Retargeted Endopepidases
US20100303788A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Galanin Retargeted Endopepidases
US8198229B2 (en) 2009-05-29 2012-06-12 Allergan, Inc. Methods of treating urogenital-neurological disorders using galanin retargeted endopepidases
US20100303756A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Urogenital-Neurological Disorders Using Interleukin Retargeted Endopepidases
US20100303783A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Urogenital-Neurological Disorders Using Tachykinin Retargeted Endopepidases
US8147848B2 (en) 2009-08-26 2012-04-03 Allergan, Inc. Method for treating premature ejaculation with a botulinum neurotoxin
EP2482838A4 (de) 2009-09-30 2013-04-10 Toxcure Inc Verwendung von botulinum-neurotoxin zur behandlung von substanzabhängigkeit
WO2012024269A2 (en) 2010-08-18 2012-02-23 Medtronic, Inc. Urgency therapy with neuromodulation and c-afferent nerve desensitization
EP2907504B1 (de) 2011-02-08 2017-06-28 Halozyme, Inc. Zusammensetzung und Lipidformulierung eines Hyaluronan-abbauenden Enzyms und seiner Verwendung zur Behandlung von benigner Prostatahyperplasie
WO2012112426A1 (en) * 2011-02-14 2012-08-23 Allergan, Inc. Arginine vasopressin retargeted clostridial endopeptidases for use in treating benign prostatic hyperplasia
US8992941B2 (en) 2011-07-08 2015-03-31 Allergan, Inc. Method for treatment of esophageal spasm
KR20140054028A (ko) 2011-07-08 2014-05-08 알러간, 인코포레이티드 자율신경계 장애의 치료방법
BR112014000634A2 (pt) 2011-07-14 2017-02-14 Allergan Inc métodos para tratamento de incontinência associada com atividade sexual
CA2841955A1 (en) 2011-07-20 2013-01-24 Allergan, Inc. Botulinum toxins for use in a method for treatment of adipose deposits
US20130171122A1 (en) * 2011-12-29 2013-07-04 Allergan, Inc. Endopeptidase and neurotoxin combination treatment of bladder disorders
CN104379127A (zh) * 2012-04-08 2015-02-25 席拉蔻公司 制备用于治疗泌尿上皮失调的热可逆凝胶制剂
US9393291B2 (en) 2012-04-12 2016-07-19 Botulinum Toxin Research Associates, Inc. Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds
US10149893B2 (en) 2013-09-24 2018-12-11 Allergan, Inc. Methods for modifying progression of osteoarthritis
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US9901627B2 (en) 2014-07-18 2018-02-27 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
RU2724776C2 (ru) * 2015-02-03 2020-06-25 Хеганес Аб (Пабл) Порошковая металлическая композиция для легкой механической обработки
MA45492A (fr) 2016-06-23 2019-05-01 Hopitaux Paris Assist Publique Vecteurs viraux pour le traitement de l'hyperactivité vésicale neurogène
WO2018038301A1 (en) 2016-08-26 2018-03-01 Hugel Inc. Stabilized liquid formulation of botulinum toxin and preparation method thereof
SI3432916T1 (sl) 2016-09-13 2020-01-31 Allergan, Inc. Stabilizirani ne-protein klostridijski toksin sestavki
EP3541358A1 (de) 2016-11-21 2019-09-25 Eirion Therapeutics, Inc. Transdermale verabreichung von grossen wirkstoffen
EP3470054B1 (de) 2017-10-11 2023-09-20 Hugel Inc. Mikrostrukturformulierungstechniken für botulinumtoxin
US10525111B2 (en) 2017-10-12 2020-01-07 Hugel, Inc. Microstructure formulation techniques for botulinum toxin
US10792400B2 (en) 2017-10-12 2020-10-06 Hugel Inc. Microstructure formulation techniques for botulinum toxin
RU2687106C1 (ru) * 2017-12-19 2019-05-07 Федеральное государственное бюджетное образовательное учреждение высшего образования "Волгоградский государственный медицинский университет" Министерства здравоохранения Российской Федерации ФГБОУ ВО ВолгГМУ МЗ РФ Способ лечения синдрома гиперактивного мочевого пузыря
LT3660509T (lt) 2018-11-29 2022-05-10 Hugel Inc. Ląstelių panaudojimu paremtas būdas botulino toksino aktyvumui nustatyti
CN110935009B (zh) * 2019-12-24 2023-07-11 云南南诏药业有限公司 科博肽制剂在制备治疗痔疮药物中的应用
RU2768606C1 (ru) * 2021-04-16 2022-03-24 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр колопроктологии имени А.Н. Рыжих" Министерства здравоохранения Российской Федерации Способ комбинированного хирургического лечения хронической анальной трещины со спазмом сфинктера методом иссечения трещины в сочетании с инъекцией ботулинического токсина типа А в дозировке 40 ЕД во внутренний анальный сфинктер под ультразвуковой навигацией

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4932936A (en) † 1988-01-29 1990-06-12 Regents Of The University Of Minnesota Method and device for pharmacological control of spasticity
JPH0642950Y2 (ja) * 1988-10-15 1994-11-09 株式会社マイコー ケース固定装置
US5919665A (en) 1989-10-31 1999-07-06 Ophidian Pharmaceuticals, Inc. Vaccine for clostridium botulinum neurotoxin
US5183462A (en) 1990-08-21 1993-02-02 Associated Synapse Biologics Controlled administration of chemodenervating pharmaceuticals
US5192751A (en) 1992-07-24 1993-03-09 Eli Lilly And Company Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence
ES2194025T3 (es) 1993-06-10 2003-11-16 Allergan Inc Toxinas botulinicas multiples para tratar trastornos y enfermedades neuromusculares.
US5437291A (en) 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
EP1486214A1 (de) 1993-12-28 2004-12-15 Allergan, Inc. Botulinusrtoxin zur Behandlung von Muskelspasmen
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
US5837265A (en) * 1996-03-08 1998-11-17 The Regents Of The University Of California Chemically-modified clostridiatoxin with improved properties
US5939070A (en) 1996-10-28 1999-08-17 Wisconsin Alumni Research Foundation Hybrid botulinal neurotoxins
US7470431B2 (en) 1997-07-15 2008-12-30 The Regents Of The University Of Colorado Use of neurotoxin therapy for treatment of urological-neurological disorders associated with prostate cancer
US7455845B2 (en) 1997-07-15 2008-11-25 The Regents Of The University Of Colorado Use of neurotoxin therapy for treatment of urologic and related disorders related to lowering elevated bladder pressure
ES2385130T3 (es) * 1997-07-15 2012-07-18 The Regents Of The University Of Colorado, A Body Corporate Uso de terapia con neurotoxinas para el tratamiento de enfermedades urológicas y de enfermedades relacionadas
US9066943B2 (en) 1997-07-15 2015-06-30 The Regents Of The University Of Colorado Use of botulinum toxin therapy for treatment of urological neurological conditions
US7449192B2 (en) 1997-07-15 2008-11-11 The Regents Of The University Of Colorado Use of neurotoxin therapy for treatment of urologic and related disorders related to neurogenic bladder dysfunction
JP3655061B2 (ja) * 1997-07-31 2005-06-02 株式会社ニデック 紫外線吸収性基材
JP2000214813A (ja) * 1999-01-22 2000-08-04 Mercury Enterprise:Kk 二輪及び三輪車輌・トラック・四輪車両へ搭載可能な可動式省エネ広告塔
US6306423B1 (en) 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
JP2002132198A (ja) * 2000-10-25 2002-05-09 Sukenori Kiuchi 三輪自転車一体型移動式回転広告塔
JP2002306290A (ja) * 2001-04-19 2002-10-22 Takumi:Kk ターンテーブル
JP2007037725A (ja) * 2005-08-02 2007-02-15 Masahiro Matsubara 多機能立方体展示ユニット
JP3121792U (ja) * 2005-10-28 2006-06-01 株式会社イマジンクリエイション ラック付３ｄレンズ使用立体型看板

Also Published As

Publication number Publication date
JP3692033B2 (ja) 2005-09-07
ATE320815T1 (de) 2006-04-15
CA2505930C (en) 2008-01-29
EP1475099A1 (de) 2004-11-10
CY1105816T1 (el) 2011-02-02
JP2001510163A (ja) 2001-07-31
CN1480212B (zh) 2013-12-04
PT2145629E (pt) 2012-04-16
WO1999003483A1 (en) 1999-01-28
CA2505933C (en) 2008-09-30
JP2010043127A (ja) 2010-02-25
ES2268567T5 (es) 2010-11-02
EP2145629A3 (de) 2010-06-09
CN1270527A (zh) 2000-10-18
DK1011695T4 (da) 2010-02-01
ATE314085T1 (de) 2006-01-15
EP1658858A3 (de) 2006-07-05
DK1475099T4 (da) 2014-05-19
JP2005089479A (ja) 2005-04-07
PT1502601E (pt) 2006-12-29
ES2336924T3 (es) 2010-04-19
EP1658858A2 (de) 2006-05-24
EP1011695B1 (de) 2006-03-22
CA2505933A1 (en) 1999-01-28
JP2007091756A (ja) 2007-04-12
AU2005234633C1 (en) 2011-02-10
CA2505930A1 (en) 1999-01-28
ES2255025T3 (es) 2006-06-16
DE69833942T2 (de) 2006-09-07
JP2007126477A (ja) 2007-05-24
CA2570406C (en) 2012-02-14
DE69833059T3 (de) 2014-12-18
HK1064044A1 (en) 2005-01-21
DE69835911T2 (de) 2007-01-11
DE69841291D1 (de) 2009-12-31
CN1803189A (zh) 2006-07-19
ES2450747T3 (es) 2014-03-25
EP1658858B2 (de) 2014-03-26
ES2256945T3 (es) 2006-07-16
DK1658858T4 (da) 2014-04-07
US20040259788A1 (en) 2004-12-23
PT1011695E (pt) 2006-07-31
DE69833942D1 (de) 2006-05-11
ATE552006T1 (de) 2012-04-15
PT1658858E (pt) 2010-02-26
JP2006104221A (ja) 2006-04-20
CN1321683C (zh) 2007-06-20
DK1475099T3 (da) 2006-03-13
ES2255025T5 (es) 2014-06-16
CN1803189B (zh) 2010-05-26
US6365164B1 (en) 2002-04-02
US6667041B2 (en) 2003-12-23
US7153514B2 (en) 2006-12-26
CN100518816C (zh) 2009-07-29
DK1949909T3 (en) 2014-03-24
US20050159337A1 (en) 2005-07-21
JP4672676B2 (ja) 2011-04-20
DE69833059D1 (de) 2006-02-02
CA2521392A1 (en) 1999-01-28
CA2296720A1 (en) 1999-01-28
EP1502601A1 (de) 2005-02-02
DE69835911T3 (de) 2011-01-13
AU8300798A (en) 1999-02-10
JP4053559B2 (ja) 2008-02-27
LU92250I2 (fr) 2013-09-10
AU743085B2 (en) 2002-01-17
ES2268567T3 (es) 2007-03-16
JP2008208136A (ja) 2008-09-11
EP1949909B1 (de) 2014-01-08
JP3955061B2 (ja) 2007-08-08
KR100544060B1 (ko) 2006-01-23
ES2256945T5 (es) 2010-03-26
EP1502601B2 (de) 2010-07-21
CA2570406A1 (en) 1999-01-28
JP2006063089A (ja) 2006-03-09
CN1939531A (zh) 2007-04-04
ATE448792T1 (de) 2009-12-15
EP1011695B2 (de) 2009-11-04
CA2296720C (en) 2008-01-29
EP1502601B1 (de) 2006-09-13
JP2005089478A (ja) 2005-04-07
ES2336924T5 (es) 2014-04-30
KR20010021941A (ko) 2001-03-15
ES2385130T3 (es) 2012-07-18
EP2145629B1 (de) 2012-04-04
EP2145629A2 (de) 2010-01-20
DK2145629T3 (da) 2012-05-29
DE69833942T3 (de) 2010-06-10
PT1949909E (pt) 2014-03-11
US20040126380A1 (en) 2004-07-01
AU2005234633B2 (en) 2007-04-19
DE69833059T2 (de) 2006-08-03
DK1011695T3 (da) 2006-05-01
EP1949909A1 (de) 2008-07-30
ATE339220T1 (de) 2006-10-15
CN1651074A (zh) 2005-08-10
CN1135988C (zh) 2004-01-28
AU2005234633A1 (en) 2005-12-15
DK1658858T3 (da) 2010-04-06
JP4815468B2 (ja) 2011-11-16
EP1475099B1 (de) 2005-12-28
CY1113355T1 (el) 2016-06-22
US20020025327A1 (en) 2002-02-28
DK1502601T4 (da) 2010-11-08
EP1011695A1 (de) 2000-06-28
DE69835911D1 (de) 2006-10-26
US7429387B2 (en) 2008-09-30
EP1658858B1 (de) 2009-11-18
LU92055I2 (fr) 2013-10-10
DK1502601T3 (da) 2007-01-15
HK1119396A1 (en) 2009-03-06
EP1011695A4 (de) 2004-05-26
EP1637157A1 (de) 2006-03-22
EP1475099B2 (de) 2014-04-09
EP2246066A1 (de) 2010-11-03
CN1480212A (zh) 2004-03-10
CY1109827T1 (el) 2014-09-10
JP4696082B2 (ja) 2011-06-08
US7001602B2 (en) 2006-02-21
HK1091750A1 (en) 2007-01-26
JP5005753B2 (ja) 2012-08-22
AU2005234633B9 (en) 2009-09-03

Similar Documents

Publication Publication Date Title
HK1091750A1 (en) Use of neurotoxin therapy for treatment of urologic and related disorders
CA2164626A1 (en) Multiple botulinum toxins for treating neuromuscular disorders and conditions
JP2003519666A5 (de)
CA2310845A1 (en) Treatment of neuromuscular disorders and conditions with different botulinum serotype
ATE215832T1 (de) Botulinumtoxin zur reduktion von migraine - kopfschmerzen
CA2180011A1 (en) Botulinum toxins for treating sweating
GEP20002146B (en) Therapeutic Peptide Derivatives
IL171607A (en) Use of botulinum toxin for the treatment of sinusitis-induced headaches
WO2003063898A3 (en) Method of treating pain with botulinum toxin
Eickenberg Interstitial concentration of antibiotics and their significance for an adequate dosage
IL149264A0 (en) Use of adatanserin for the treatment of neurodegenerative conditions
CA2165271A1 (en) Reduction of adipose tissue
CA2590537A1 (en) The use of the neurotoxin component of a botulinum toxin for the treatment of excessive lacrimation

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20180714